Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis-Reference-Cited by-同舟云学术

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

Published:2017-08 Issue:8 Volume:23 Page:1394-1402
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Taxonera Carlos,Rodríguez Cristina,Bertoletti Federico,Menchén Luís,Arribas Julia,Sierra Mónica,Arias Lara,Martínez-Montiel Pilar,Juan Alba,Iglesias Eva,Algaba Alicia,Manceñido Noemí,Rivero Montserrat,Barreiro-de Acosta Manuel,López-Serrano Pilar,Argüelles-Arias Federico,Gutierrez Ana,Busquets David,Gisbert Javier P.,Olivares David,Calvo Marta,Alba Cristina

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference23 articles.

1. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

2. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

3. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

4. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

5. Adalimumab in active ulcerative colitis: A “real-life” observational study

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis;PLOS ONE;2024-08-29

2. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry;Therapeutic Advances in Gastroenterology;2024-01

3. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East;Therapeutic Advances in Gastroenterology;2024-01

4. Therapeutic advancement in inflammatory bowel disease by incorporating plant-based diet;Translational Gastroenterology and Hepatology;2023-10

5. Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease;Digestive Diseases and Sciences;2023-09-19